1. Home
  2. EU vs SENS Comparison

EU vs SENS Comparison

Compare EU & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enCore Energy Corp.

EU

enCore Energy Corp.

HOLD

Current Price

$1.86

Market Cap

413.7M

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$6.43

Market Cap

300.1M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
EU
SENS
Founded
2009
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Industrial Machinery/Components
Sector
Basic Materials
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
413.7M
300.1M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
EU
SENS
Price
$1.86
$6.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$4.00
$18.38
AVG Volume (30 Days)
2.1M
263.2K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
N/A
N/A
Revenue
$43,155,000.00
$16,389,000.00
Revenue This Year
$212.11
$74.15
Revenue Next Year
$29.88
$58.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.85
52 Week Low
$1.51
$0.41
52 Week High
$4.19
$8.75

Technical Indicators

Market Signals
Indicator
EU
SENS
Relative Strength Index (RSI) 42.37 41.51
Support Level $1.81 $6.17
Resistance Level $2.17 $6.87
Average True Range (ATR) 0.13 0.29
MACD 0.00 0.01
Stochastic Oscillator 30.87 6.42

Price Performance

Historical Comparison
EU
SENS

About EU enCore Energy Corp.

enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: